8-K: Artivion Soars on Strong Q3, Raises 2025 Outlook

Artivion, Inc. reported exceptionally strong third-quarter 2025 financial results, driven by robust revenue growth and significant adjusted EBITDA increase, leading to raised full-year guidance.

Summary

• Achieved total revenues of $113.4 million in Q3 2025, an 18% increase on a GAAP basis and 16% on a non-GAAP constant currency basis compared to Q3 2024.
• Reported net income of $6.5 million, or $0.13 per fully diluted share, in Q3 2025, a significant improvement from a net loss of $(2.3) million, or $(0.05) per share, in Q3 2024.
• Non-GAAP net income for Q3 2025 was $7.9 million, or $0.16 per fully diluted share, up from $5.0 million, or $0.12 per share, in Q3 2024.
• Adjusted EBITDA increased by 39% to $24.6 million in Q3 2025, compared to $17.7 million in Q3 2024.
• Enrolled the first patient in the ARTIZEN U.S. Investigational Device Exemption (IDE) trial for Arcevo.
• Refinanced the existing credit agreement, extending the maturity date to 2031, securing a more favorable interest rate, and gaining access to a new $150 million delayed draw term loan facility.
• Raised the midpoint of full-year 2025 constant currency revenue guidance to 13% to 14% growth, with reported revenues expected between $439 million and $445 million.
• Raised the midpoint of full-year 2025 adjusted EBITDA guidance to 24% to 28% growth, with adjusted EBITDA expected between $88 million and $91 million.

Sentiment

Score: 9

Explanation: The filing presents exceptionally strong financial results, significant operational progress in clinical trials, and a strengthened balance sheet. The company also raised its full-year guidance for both revenue and adjusted EBITDA, indicating strong positive momentum and confidence in future performance. The only minor detractions are general risks inherent in the industry and the mention of a past cybersecurity incident, which is being managed.

Positives

• Total revenues increased by 18% GAAP and 16% constant currency to $113.4 million in Q3 2025.
• Net income significantly improved to $6.5 million in Q3 2025 from a net loss of $(2.3) million in Q3 2024.
• Non-GAAP net income grew to $7.9 million in Q3 2025 from $5.0 million in Q3 2024.
• Adjusted EBITDA surged by 39% to $24.6 million in Q3 2025.
• Strong product segment growth: stent grafts up 38% (31% constant currency), On-X up 25% (23% constant currency), preservation services up 5% (5% constant currency), and BioGlue up 2% (1% constant currency).
• Successful enrollment of the first patient in the ARTIZEN U.S. IDE trial for Arcevo, marking a key clinical milestone.
• Presentation of new favorable clinical data from AMDS PERSEVERE and PROTECT trials, validating positive clinical benefits.
• Strengthened balance sheet through credit agreement refinancing, extending maturity to 2031 and securing a more favorable interest rate.
• Gained access to a new $150 million delayed draw term loan facility, enhancing financial flexibility.
• Raised full-year 2025 constant currency revenue guidance midpoint to 13-14% growth.
• Raised full-year 2025 adjusted EBITDA guidance midpoint to 24-28% growth, expecting adjusted EBITDA of $88-$91 million.
• Net cash flows from operating activities for the nine months ended September 30, 2025, increased to $20.3 million from $12.1 million in the prior year.
• Free cash flows for the nine months ended September 30, 2025, increased to $8.8 million from $2.3 million in the prior year.

Risks

• The unpredictability of the timing and outcome of regulatory decisions and other regulatory developments.
• Risks relating to international operations.
• The benefits anticipated from the 2024 credit facility and the 2025 amendments thereof, the Ascyrus Medical LLC transaction, Endospan agreements, and operational improvements in the tissue and stent graft business may not be achieved at all or at the levels anticipated.
• The benefits anticipated from clinical trials and regulatory approvals may not be achieved or achieved on anticipated timelines.
• Uncertainty regarding potential unknown or future impacts of the November 2024 cybersecurity incident, including the extent to which the company is able to recover against its insurance policies.
• The benefits anticipated from expansion into APAC and LATAM may not be achieved or achieved on anticipated timelines.

Future Outlook

Artivion is raising the midpoint of its full-year 2025 constant currency revenue guidance to 13% to 14% growth, with reported revenues now expected to be in the range of $439 million to $445 million. The company also raised the midpoint of its adjusted EBITDA guidance, expecting growth of 24% to 28% for the full year, resulting in an adjusted EBITDA range of $88 million to $91 million. Management remains confident in its ability to grow adjusted EBITDA at twice the rate of constant currency revenue growth.

Management Comments

• "Our third quarter performance was exceptionally strong as we made progress across each of our strategic initiatives while delivering 16% constant currency revenue growth."
• "In addition to our strong commercial results, we saw continued progress with our market expanding clinical programs. We enrolled the first patient in our ARTIZEN trial for Arcevo, marking an important milestone."
• "new favorable clinical data from our AMDS PERSEVERE and PROTECT trials were presented in two late-breaking science sessions at the European Association for Cardio-Thoracic Surgery, which further validated the positive clinical benefits of our AMDS technology."
• "We also took strategic steps to strengthen our balance sheet by refinancing our existing credit agreement to extend the maturity date to 2031, secure a more favorable interest rate, and gain access to a new $150 million delayed draw term loan facility."
• "Given our strong third quarter performance and continued business momentum, we are raising the midpoints of our full year 2025 constant currency revenue and EBITDA guidance and remain confident in our ability to grow adjusted EBITDA at twice the rate of constant currency revenue growth."

Industry Context

Artivion's strong performance in cardiac and vascular surgery, particularly with stent grafts and On-X mechanical heart valves, indicates robust demand within the aortic disease treatment market. The progress in clinical trials for Arcevo and positive data for AMDS technology suggest continued innovation and potential for market expansion, aligning with the broader medical device industry's focus on advanced surgical solutions and clinical evidence.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Likely positive impact due to strong financial performance, increased profitability, raised guidance, and a strengthened balance sheet, potentially leading to increased share value.
• Creditors: Positive impact from the refinancing of the credit agreement, extending debt maturity to 2031 and securing more favorable interest rates, reducing immediate financial risk.
• Patients/Customers: Potential positive impact from continued progress in clinical programs (ARTIZEN trial for Arcevo, AMDS technology data), suggesting future availability of advanced treatment options for aortic diseases.
• Employees: Strong company performance and growth could lead to job security and potential opportunities, though not explicitly stated.

Next Steps

• Continue the ARTIZEN U.S. Investigational Device Exemption trial for Arcevo.
• Leverage new favorable clinical data from AMDS PERSEVERE and PROTECT trials.
• Execute on the full-year 2025 financial outlook, aiming for 13-14% constant currency revenue growth and 24-28% adjusted EBITDA growth.
• Grow adjusted EBITDA at twice the rate of constant currency revenue growth.

Key Dates

Recommendation

Artivion's Q3 2025 results demonstrate exceptional financial and operational strength, significantly outperforming prior periods and leading to a raised full-year outlook. The company achieved substantial revenue growth, a strong return to net income, and a 39% increase in adjusted EBITDA. Strategic moves like the credit refinancing have strengthened the balance sheet and provided additional liquidity. Progress in key clinical trials (Arcevo, AMDS) indicates future growth drivers. The combination of robust current performance, positive future guidance, and strategic financial management makes Artivion a compelling investment opportunity.

Keywords

Artivion, AORT, Q3 2025 Earnings, Financial Results, Cardiac Surgery, Vascular Surgery, Aortic Disease, Stent Grafts, On-X Heart Valves, Surgical Sealants, Preservation Services, Arcevo, ARTIZEN trial, AMDS technology, Adjusted EBITDA, Revenue Growth, Credit Refinancing, Medical Devices,